News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Penn Researchers Add More Evidence To Demonstrate Role Of COX Inhibitors In Heart-Disease Risk


10/19/2005 5:12:24 PM

In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk. In one, a statistical meta-analysis of two placebo-controlled trials, the COX-2 inhibitor Bextra elevated the combined incidence of heart attack and stroke three-fold in coronary artery bypass graft (CABG) surgery patients. In the second, the investigators found that a fat produced by COX-1 speeds hardening of the arteries in a mouse model of atherosclerosis, which may have implications for low-dose aspirin therapy in heart patients.

Read at EurekAlert!
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES